SUBSCRIBE
SUBSCRIBE

Genentech, Inc.

NEWS
Chronic lymphocytic leukemia
FDA
Imbruvica-Rituximab Combo Approved by FDA for Chronic Lymphocytic Leukemia
The FDA recently approved the combination of Imbruvica-Rituximab for treating chronic lymphocytic leukemia. Here’s everything you need to know.
April 22, 2020
 · 
2 min read
 · 
Mark Terry
Drug Development
Clinical Catch-Up: March 23-27
Although some clinical trials are being slowed or halted, others are reporting out data. Here’s a look.
March 27, 2020
 · 
8 min read
 · 
Mark Terry
jejim/Shutterstock
Policy
Genentech’s Xofluza Submitted to FDA for New Children’s Formulations
The NDA is for a new formulation of the drug as one-dose granules for oral suspension, would which largely be aimed at children and people who have difficulty swallowing.
March 27, 2020
 · 
2 min read
 · 
Mark Terry
BioCapital
In Other (Biopharma) News: This Week’s Non-Coronavirus Stories
BioSpace takes a quick look at some recent, key industry news that is not related to the coronavirus.
March 25, 2020
 · 
4 min read
 · 
Alex Keown
BioCapital
Clinical Catch-Up: March 16-20
Here’s a look at some of last week’s clinical trial news.
March 20, 2020
 · 
7 min read
 · 
Mark Terry
Drug Development
Biopharma Industry News for March 20: Update on the Novel Coronavirus
A summary of daily Biopharma industry news. Please check out stories that are trending on March 20, 2020.
March 20, 2020
 · 
5 min read
 · 
BioSpace Editorial Staff
Drug Development
Biopharma Industry News for March 19: Update on the Novel Coronavirus
A summary of daily Biopharma industry news. Please check out stories that are trending on March 19, 2020.
March 19, 2020
 · 
3 min read
 · 
BioSpace Editorial Staff
Policy
Genentech’s Esbriet Granted Breakthrough Therapy Designation for uILD
The FDA granted the designation based on data from a mid-stage trial that examined the safety and efficacy of Esbriet in this indication.
March 4, 2020
 · 
2 min read
 · 
Alex Keown
Business
Bicycle and Genentech Forge Immuno-Oncology Collaboration Worth up to $1.7 Billion
In its announcement, Bicycle did not identify the cancer targets it will focus on in its collaboration with Genentech.
February 25, 2020
 · 
2 min read
 · 
Alex Keown
Load More
AWARDS
  • 2022 Best Places to Work
  • 2023 Best Places to Work
  • 2024 Best Places to Work
JOBS
IN THE PRESS
Policy
FDA Accepts Genentech’s Biologics License Application for Fixed-dose Subcutaneous Combination of Perjeta and Herceptin for HER2-Positive Breast Cancer
February 25, 2020
 · 
14 min read
Policy
FDA Grants Priority Review to Genentech’s Tecentriq Monotherapy as First-line Treatment of Certain People With Advanced Non-small Cell Lung Cancer
February 19, 2020
 · 
10 min read
Drug Development
Genentech Provides Topline Results From Investigator-Led Phase II/III Trial With Gantenerumab in Rare Inherited Form of Alzheimer’s Disease
February 10, 2020
 · 
6 min read
Biotech Bay
Genentech’s Risdiplam Showed Significant Improvement in Motor Function in People Aged 2-25 With Type 2 or 3 Spinal Muscular Atrophy
February 6, 2020
 · 
7 min read
Policy
Genentech Submits Supplemental Biologics License Application to the FDA for Tecentriq in Combination With Avastin for the Most Common Form of Liver Cancer
January 27, 2020
 · 
17 min read
Drug Development
Genentech Provides an Update on Phase III Study of Tecentriq in People With Muscle-invasive Urothelial Cancer
January 24, 2020
 · 
8 min read
Biotech Bay
Genentech’s Risdiplam Meets Primary Endpoint in Pivotal FIREFISH Trial in Infants With Type 1 Spinal Muscular Atrophy
January 23, 2020
 · 
5 min read
Drug Development
Genentech Announces Phase III Study Results for Tecentriq Plus Cotellic and Zelboraf in People With Previously Untreated BRAF V600 Mutation-positive Advanced Melanoma
December 13, 2019
 · 
23 min read
Pharm Country
Matinas BioPharma Announces Feasibility Evaluation with Third Large Biopharmaceutical Company for the Formulation of Compounds Utilizing LNC Delivery Platform
December 12, 2019
 · 
4 min read
Drug Development
Data From Phase 3 Trial Evaluating Fixed-Dose Subcutaneous Combination Of Perjeta® And Herceptin® Using Halozyme’s ENHANZE® Drug Delivery Technology To Be Presented At San Antonio Breast Cancer Symposium
December 12, 2019
 · 
6 min read
Load More